

Non-QPP Measures

#	Measure ID	Measure Title	Definition	Historical Benchmark?	Type	Domain
1	AQUA8 [^]	Hospital admissions or infectious complications within 30 days of TRUS Biopsy	Percentage of patients with infection, inpatient consultation, or hospital admission for infection or sepsis within 30 days of undergoing a TRUS biopsy	No	Outcome	Patient Safety
2	AQUA14 [^]	Stones: Repeat Shock Wave Lithotripsy (SWL) Within 6 Months of Initial Treatment	Percentage of patients who underwent repeat Shock Wave Lithotripsy within 6 months of initial procedure	Yes	Outcome	Effective Clinical Care
3	AQUA15 [^]	Stones: Urinalysis Performed Before Surgical Stone Procedures	Percentage of patients with a documented urinalysis 30 days before surgical stone procedures	Yes	Process	Patient Safety
4	AQUA16	Non-Muscle Invasive Bladder Cancer: Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease	Percentage of patients with T1 disease who had a second transurethral resection of bladder tumor (TURBT) within 6 weeks of the initial TURBT	No	Process	Effective Clinical Care
5	AQUA18	Non-Muscle Invasive Bladder Cancer: Early Surveillance Cystoscopy for Non-Muscle Invasive Bladder Cancer	Percentage of patients who had surveillance cystoscopy 12 to 16 weeks after undergoing initial Transurethral Resection for Bladder Tumor (TURBT)	No	Process	Effective Clinical Care
6	AQUA26 [^]	Benign Prostate Hyperplasia (BPH): Inappropriate Lab & Imaging Services for Patients with BPH	Percentage of patients with initial diagnosis of BPH who had a creatinine lab order placed or had a CT abdomen, MRI abdomen, ultrasound abdomen ordered or performed	Yes	Process	Efficiency and Cost Reduction

Non-QPP Measures

#	Measure ID	Measure Title	Definition	Historical Benchmark?	Type	Domain
7	MUSIC4 ^{^†}	Prostate Cancer: Active surveillance/watchful waiting for low-risk prostate cancer	Percentage of patients with low-risk prostate cancer receiving active surveillance or watchful waiting	No	Process	Effective Clinical Care
8	MUSIC10 [†]	Prostate Cancer: Confirmation Testing in low risk active surveillance eligible patients	Percentage of low risk patients that are eligible for active surveillance who receive confirmation testing within 6 months of diagnosis	No	Process	Effective Clinical Care
9	MUSIC11 [†]	Prostate Cancer: Follow-Up Testing for patients on active surveillance for at least 30 months	Percentage of patients on active surveillance that have 2 or more tumor burden reassessments and 3 PSA tests in first 30 months since diagnosis	No	Process	Effective Clinical Care

QPP Measures

#	QPP #	Measure Title	Definition	Historical Benchmark?	Type	Domain
10	1 [^]	Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)	Percentage of patient 18-75 years of age with diabetes who had hemoglobin A1c>9.0% during the measurement period	Yes	Intermediate Outcome	Effective Clinical Care
11	eCQM* CMS122v10			Yes		
12	47 [^]	Advance Care Plan	Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan	Yes	Process	Communication & Care Coordination
13	48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	Percentage of female patients aged 65 years and older who were assessed for the presence or absence of urinary incontinence within 12 months	Yes	Process	Effective Clinical Care
14	50 [^]	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence with a documented plan of care for urinary incontinence at least once within 12 months	Yes	Process	Person & Caregiver-Centered Experience & Outcomes

QPP Measures

#	QPP #	Measure Title	Definition	Historical Benchmark?	Type	Domain
15	102 [^]	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, who did not have a bone scan performed at any time since diagnosis of prostate cancer	No	Process	Efficiency and Cost Reduction
16	eQCM* CMS129v11			No		
17	104	Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed androgen deprivation therapy in combination with external beam radiotherapy to the prostate	Yes	Process	Effective Clinical Care
18	110	Preventative Care and Screening: Influenza Immunization	Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization	Yes	Process	Community/ Population Health
19	eQCM* CMS147v11			Yes		
20	111	Pneumococcal Vaccination Status for Older Adults	Percentage of patients 66 years of age and older who have ever received a pneumococcal vaccine	Yes	Process	Community/ Population Health
21	eQCM* CMS127v10			Yes		
22	112	Breast Cancer Screening	Percentage of women 50-74 years of age who had a mammogram to screen for breast cancer in the 27 months prior to the end of the measurement period	Yes	Process	Effective Clinical Care
23	eQCM* CMS125v10			Yes		

*Electronic Clinical Quality Measure ^High Priority Measure

† ©2011 The Regents of the University of Michigan. Original MUSIC measure developed by the University of Michigan as part of the Michigan Urological Surgery Improvement Collaborative. All Rights Reserved.

QPP Measures

#	QPP #	Measure Title	Definition	Historical Benchmark?	Type	Domain
24	113	Colorectal Cancer Screening	Percentage of patients 50-75 years of age who had appropriate screening for colorectal cancer	Yes	Process	Effective Clinical Care
25	eCQM* CMS130v10			Yes		
26	117	Diabetes: Eye Exam	Percentage of patients 18-75 years of age with diabetes and an active diagnosis of retinopathy in any part of the measurement period who had a retinal or dilated eye exam by an eye care professional during the measurement period or diabetics with no diagnosis of retinopathy in any part of the measurement period who had a retinal or dilated eye exam by an eye care professional during the measurement period or in the 12 months prior to the measurement period	Yes	Process	Effective Clinical Care
27	eCQM* CMS131v10			Yes		
28	119	Diabetes: Medical Attention for Nephropathy	The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period	Yes	Process	Effective Clinical Care
29	eCQM* CMS134v10			Yes		
30	128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan	Percentage of patients aged 18 years and older with a BMI documented during the current encounter or within the previous twelve months AND who had a follow-up plan documented if most recent BMI was outside of normal parameters	Yes	Process	Community Population Health
31	eCQM* CMS69v10			Yes		

QPP Measures

#	QPP #	Measure Title	Definition	Historical Benchmark?	Type	Domain
32	130 [^]	Documentation of Current Medications in the Medical Record	Percentage of visits for patients aged 18 years and older for which the eligible professional or eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter	Yes	Process	Patient Safety
33	eCQM* CMS68v11			Yes		
34	134	Preventive Care and Screening: Screening for Depression and Follow-Up Plan	Percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the eligible encounter	Yes	Process	Community/ Population Health
35	eCQM* CMS2v11			Yes		
36	226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within the measurement period AND who received tobacco cessation intervention on the date of the encounter or within the previous 12 months if identified as a tobacco user.	No	Process	Community/ Population Health
37	eCQM* CMS138v10			No		
38	236 [^]	Controlling High Blood Pressure	Percentage of patients 18-85 years of age who had a diagnosis of essential hypertension starting before and continuing into, or starting during the first six months of the measurement period, and whose most recent blood pressure was adequately controlled (<140/90mmHg) during the measurement period.	Yes	Intermediate Outcome	Effective Clinical Care
39	eCQM* CMS165v10			Yes		

QPP Measures

#	QPP #	Measure Title	Definition	Historical Benchmark?	Type	Domain
40	265 [^]	Biopsy Follow-Up	Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient	Yes	Process	Communication & Care Coordination
41	317	Preventive Care and Screening: Screening for High Blood Pressure Follow-up Documented	Percentage of patient visits for patients aged 18 years and older seen during the measurement period who were screened for high blood pressure AND a recommended follow-up plan is documented, as indicated, if blood pressure is elevated or hypertensive	No	Process	Community/ Population Health
42	eCQM* CMS22v10			No		
43	318 [^] eCQM* CMS139v10 version only	Falls: Screening for Future Fall Risk	Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period	Yes	Process	Patient Safety
44	357 [^]	Surgical Site Infection	Percentage of patients aged 18 years and older who had a surgical site infection (SSI)	Yes	Outcome	Effective Clinical Care
45	358 [^]	Patient-Centered Surgical Risk Assessment and Communication	Percentage of patients who underwent a non-emergency surgery who had their personalized risks of postoperative complications assessed by their surgical team prior to surgery using a clinical data-based, patient-specific risk calculator and who received personal discussion of those risks with the surgeon	Yes	Process	Person & Caregiver-Centered Experience & Outcomes

QPP Measures

#	QPP #	Measure Title	Definition	Historical Benchmark?	Type	Domain
46	370 [^]	Depression Remission at Twelve Months	The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event date	No	Outcome	Effective Clinical Care
47	eCQM* CMS159v10			Yes	Outcome	Effective Clinical Care
48	374 [^]	Closing the Referral Loop: Receipt of Specialist Report	Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred	Yes	Process	Communication & Care Coordination
49	eCQM* CMS50v10			Yes		
50	431	Preventive Care and Screening Unhealthy Alcohol Use: Screening & Brief Counseling	Percentage of patients aged 18 years and older who were screened for unhealthy alcohol use using a systematic screening method at least once within the last 24 months AND who received brief counseling if identified as an unhealthy alcohol user	No	Process	Community/ Population Health
51	432 [^]	Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair	Percentage of patients undergoing pelvic organ prolapse repairs who sustain an injury to the bladder recognized either during or within 30 days after surgery	No	Outcome	Patient Safety
52	433 [^]	Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair	Percentage of patients undergoing surgical repair of pelvic organ prolapse that is complicated by a bowel injury at the time of index surgery that is recognized intraoperatively or within 30 days after surgery	No	Outcome	Patient Safety

QPP Measures

#	QPP #	Measure Title	Definition	Historical Benchmark?	Type	Domain
53	438			Yes		
54	eCQM* CMS347v5	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period: *All patients who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD), including an ASCVD procedure; OR *Patients aged ≥ 20 years who have ever had a low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial hypercholesterolemia; OR *Patients aged 40-75 years with a diagnosis of diabetes	Yes	Process	Effective Clinical Care
55	462 eCQM* CMS645v5 version only	Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy	Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT	No	Process	Effective Clinical Care

QPP Measures

#	QPP #	Measure Title	Definition	Historical Benchmark?	Type	Domain
56	476[^] eCQM* CMS771v3 version only	Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia	Percentage of patients with an office visit within the measurement period and with a new diagnosis of clinically significant Benign Prostatic Hyperplasia who have an International Prostate Symptom Score (IPSS) or American Urological Association (AUA) Symptom Index (SI) documented at the time of diagnosis and again 6-12 months later with an improvement of 3 points	No	Outcome	Person and Caregiver-Centered Experience and Outcomes
57	481[^] eCQM* CMS646v2 version only	Intravesical Bacillus-Calmette Guerin for Non-muscle Invasive Bladder Cancer	Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging	No	Process	Effective Clinical Care